Publication:
Pulmonary hypertension in patients with sarcoidosis: A single-center experience

dc.contributor.authorsOzen, Deniz Kaplan; Mutlu, Bulent; Kocakaya, Derya; Turan, Burak; Sekerci, Sena Sert; Ceyhan, Berrin
dc.date.accessioned2022-03-14T09:56:41Z
dc.date.accessioned2026-01-11T06:02:56Z
dc.date.available2022-03-14T09:56:41Z
dc.date.issued2020
dc.description.abstractObjective: Sarcoidosis is a systemic granulomatous disease rarely complicated by pulmonary hypertension (PH). The prevalence of PH in sarcoidosis is unclear and has differences between ethnic groups. This study aimed to investigate the prevalence and predictors of PH in a Turkish cohort. Methods: The study included 55 patients with biopsy-proven sarcoidosis in a single center. All patients underwent detailed transthoracic echocardiography (TTE) to assess the probability of PH as recommended. Right heart catheterization (RHC) was performed for patients with intermediate-high risk of PH. Patients with mean pulmonary artery pressure >20 mm Hg by RHC were defined as PH. Demographic and clinical characteristics, laboratory data, spirometry, 6-min walk test, and TTE were compared between low and intermediate-high risk PH groups. Results: The probability of PH was low with 47 patients. Eight patients had intermediate-high probability of PH, and two of them refused to undergo RHC. Of six intermediate-high probability patients, three had PH, and all of them had post-precapillary PH. The prevalence of PH in sarcoidosis was 5.5% (3/55). Six-minute walk distance (6 MWD) and diastolic parameters (E/A ratio, E' wave, and left atrial volume) were significantly lower, and New York Heart association class and N-terminal probrain natriuretic peptide (NT-proBNP) level were higher in intermediate-high risk PH patients compared with low-risk PH patients. Conclusion: The frequency of PH in sarcoidosis was 5.5% in a Turkish cohort. NT-proBNP, 6 MWD, diastolic function parameters, and myocardial strain parameters can be useful predictors of PH in patients with sarcoidosis, besides known echocardiographic parameters.
dc.identifier.doi10.14744/AnatolJCardiol.2020.88054
dc.identifier.eissn2149-2271
dc.identifier.issn2149-2263
dc.identifier.pubmed33382054
dc.identifier.urihttps://hdl.handle.net/11424/243731
dc.identifier.wosWOS:000604958700009
dc.language.isoeng
dc.publisherAVES
dc.relation.ispartofANATOLIAN JOURNAL OF CARDIOLOGY
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectbrain natriuretic peptide
dc.subjectsarcoidosis
dc.subject6-minute walk test
dc.subjectpulmonary hypertension
dc.subjectSPECKLE TRACKING ECHOCARDIOGRAPHY
dc.subjectARTERIAL-HYPERTENSION
dc.subjectEUROPEAN ASSOCIATION
dc.subjectAMERICAN SOCIETY
dc.subjectRECOMMENDATIONS
dc.subjectGUIDELINES
dc.subjectOUTCOMES
dc.subjectUPDATE
dc.titlePulmonary hypertension in patients with sarcoidosis: A single-center experience
dc.typearticle
dspace.entity.typePublication
oaire.citation.endPage41
oaire.citation.issue1
oaire.citation.startPage36
oaire.citation.titleANATOLIAN JOURNAL OF CARDIOLOGY
oaire.citation.volume25

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
file.pdf
Size:
340.99 KB
Format:
Adobe Portable Document Format